95-12193. Prospective Grant of Exclusive License: Polysaccharide-Protein Conjugates  

  • [Federal Register Volume 60, Number 96 (Thursday, May 18, 1995)]
    [Notices]
    [Page 26732]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 95-12193]
    
    
    
    -----------------------------------------------------------------------
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Prospective Grant of Exclusive License: Polysaccharide-Protein 
    Conjugates
    
    AGENCY: National Institutes of Health, Public Health Service, DHHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: This notice is in accordance with 15 U.S.C. 209(c)(1) and 37 
    CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
    Department of Health and Human Services, is contemplating the grant of 
    an exclusive world-wide license to practice the invention embodied in 
    U.S. Patent Number 5,204,098 entitled ``Polysaccharide-Protein 
    Conjugates'' and related foreign patent applications to Connaught 
    Laboratories, Inc., of Swiftwater, Pennsylvania. The patent rights in 
    this invention have been assigned to the United States of America.
        The prospective exclusive license will be royalty-bearing and will 
    comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
    It is anticipated that this license will be limited to the field of 
    typhoid vaccines and typhoid Vi-protein conjugates for the prevention 
    of typhoid fever in humans. This prospective exclusive license may be 
    granted unless within 60 days from the date of this published notice, 
    NIH receives written evidence and argument that establishes that the 
    grant of the license would not be consistent with the requirements of 
    35 U.S.C. 209 and 37 CFR 404.7.
        The patent describes conjugates of bacterial capsular 
    polysaccharides and carrier proteins, and methods of synthesis, wherein 
    the polysaccharide and protein are linked through a thio derivative of 
    a carboxyl group found on the polysaccharide. The conjugates are useful 
    as vaccines for prevention of disease caused by infection by the 
    bacterial species from which the capsular polysaccharide is derived.
    
    ADDRESSES: Requests for a copy of this patent, inquiries, comments and 
    other materials relating to the contemplated license should be directed 
    to: Robert Benson, Patent Advisor, Office of Technology Transfer, 
    National Institutes of Health, 6011 Executive Blvd., Box 13, Rockville, 
    MD 20852. Telephone: (301) 496-7056, X267; Facsimile: (301) 402-0220. 
    Applications for a license filed in response to this notice will be 
    treated as objections to the grant of the contemplated license. Only 
    written comments and/or applications for a license which are received 
    by NIH on or before July 17, 1995, will be considered.
    
        Dated: May 5, 1995.
    Barbara M. McGarey,
    Deputy Director, Office of Technology Transfer.
    [FR Doc. 95-12193 Filed 5-17-95; 8:45 am]
    BILLING CODE 4140-01-P
    
    

Document Information

Published:
05/18/1995
Department:
Health and Human Services Department
Entry Type:
Notice
Action:
Notice.
Document Number:
95-12193
Pages:
26732-26732 (1 pages)
PDF File:
95-12193.pdf